Pharmaceutical Transparency

---

Can Do MS’s programs enhance and complement traditional models of care by focusing on the physical, interpersonal, emotional, intellectual and spiritual aspects of living with MS. We believe that pharmaceutical therapies are one part of the overall care plan for people living with multiple sclerosis. We work to educate those with MS, as well as medical and pharmaceutical professionals, on our whole-person, whole-health, whole-community philosophy to maximizing health and living with MS.

Many pharmaceutical companies recognize that our programs can complement the therapies they offer.  When grant or sponsorship funds are provided by pharmaceutical companies to help support our programs that require outside funding, such as CAN DO or JUMPSTART Programs, or our webinars, the pharmaceutical companies do not have input into the content of these programs or direct how these funds will be spent in the service of our mission.

In 2011 Can Do MS’s total revenue was $1,544,415; below is a breakdown of pharmaceutical contributions included in this.

2011 Pharmaceutical Contribution:

• Total Pharmaceutical Revenue: $645,103.75

• Percentage of Total Organizational Revenue: 42%

• Event Sponsorship: $160,000

• Program Grants: $485,103.75

Total contributions by companies without an MS product on market in 2011:

• Genentech: $100,000

• Genzyme: $26,750

Total contributions by companies with an MS product on market in 2011:

• Acorda: $10,000

• Allergan: $25,000

• Bayer: $50,000

• Biogen: $179,103.75

• EMD Serono: $150,000

• Novartis: $84,150

• Pfizer: $5,000

• Questcor: $5,000

• Teva: $45,000 

Can Do MS’s Position Regarding Its Relationship with the Pharmaceutical Industry
Can Do MS envisions a world in which all people impacted by MS maximize their potential, improving their quality of life. It is our mission to lead the way with comprehensive programs that empower people and families living with MS to transform and improve their quality of life.

We work to educate those with MS, as well as medical and pharmaceutical professionals, on our whole-person, whole-health, whole-community philosophy to maximizing health and living with MS.

Many pharmaceutical companies recognize that our programs can complement the therapies they offer. When grant or sponsorship funds are provided by pharmaceutical companies to help support our programs that require outside funding, such as CAN DO or JUMPSTART Programs, or our webinars, the pharmaceutical companies do not have input into the content of these programs or direct how these funds will be spent in the service of our mission.